Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 ...

With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, ...

Children, adolescents and those with weakened immune systems have been particularly vulnerable to mpoxThe World Health ...

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in ...

Two recent studies indicate that the efficacy of Bavarian Nordic’s vaccine against Mpox diminishes to undetectable levels within 6 to 12 months. This discovery raises concerns about long-term ...

The World Health Organization approved the use of Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, ...

The World Health Organization (WHO) announced on Monday that it has approved the Bavarian Nordic mpox vaccine, known as Jynneos, for adolesc..|News Track ...

LONDON, Sept 19 (Reuters) - Bavarian Nordic (BAVA.CO), opens new tab said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using ...

WHO has approved Bavarian Nordic's mpox vaccine for adolescents, expanding access as global concern over the viral outbreak ...

The World Health Organization has approved the Bavarian Nordic's Jynneos vaccine for adolescents aged 12 to 17, a group at ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 ...